Why insider trading matters?

Numerous studies have examined whether there is evidence that U.S. insiders systematically trade on private information despite the legal deterrence. The consensus appears to be that insider purchases (but not sales) tend to be followed by positive abnormal stock price performance, particularly for small growth stocks.

- Prof. B. Espen Eckbo, Dartmouth College
Retrophin, Inc. (RTRX)
Sector: Healthcare; Industry: Biotechnology

Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-05-12 Rosenberg Noah L. Chief Medical Officer Sell 750 $19.30 $14,475 No
2021-05-12 REED ELIZABETH E SVP, GC & Corporate Secretary Sell 3,250 $19.30 $62,725 No
2021-05-12 Clague Laura Chief Financial Officer Sell 4,000 $19.30 $77,200 No
2021-05-11 ASELAGE STEVE Director Sell 2,146 $19.58 $42,023 No
2021-04-16 ASELAGE STEVE Director Sell 10,000 $26.23 $262,300 Yes
2021-03-17 ASELAGE STEVE Director Sell 17,727 $27.44 $486,456 Yes
2021-02-18 ROTE WILLIAM E. Senior Vice President, R&D Sell 2,500 $28.01 $70,025 No
2021-02-08 Rosenberg Noah L. Chief Medical Officer Sell 2,250 $31.50 $70,864 No
2021-02-08 Heerma Peter Chief Commercial Officer Sell 2,250 $31.50 $70,864 No
2021-02-08 ROTE WILLIAM E. Senior Vice President, R&D Sell 4,500 $31.50 $141,728 No
2021-02-08 REED ELIZABETH E SVP, GC & Corporate Secretary Sell 4,500 $31.50 $141,728 No
2021-02-08 Clague Laura Chief Financial Officer Sell 4,500 $31.50 $141,728 No
2021-02-08 Dube Eric M Chief Executive Officer Sell 9,626 $31.50 $303,171 No
2021-02-03 Heerma Peter Chief Commercial Officer Sell 1,126 $29.83 $33,589 No
2021-02-03 Rosenberg Noah L. Chief Medical Officer Sell 1,813 $28.91 $52,414 No
2021-02-03 ROTE WILLIAM E. Senior Vice President, R&D Sell 3,625 $28.91 $104,799 No
2021-02-03 REED ELIZABETH E SVP, GC & Corporate Secretary Sell 3,175 $28.91 $91,789 No
2021-02-03 Clague Laura Chief Financial Officer Sell 3,625 $28.91 $104,799 No
2021-02-03 Dube Eric M Chief Executive Officer Sell 2,406 $28.91 $69,557 No
2021-02-02 Rosenberg Noah L. Chief Medical Officer Sell 1,813 $30.75 $55,750 No
2021-02-02 ROTE WILLIAM E. Senior Vice President, R&D Sell 3,625 $30.75 $111,469 No
2021-02-02 REED ELIZABETH E SVP, GC & Corporate Secretary Sell 3,175 $30.75 $97,631 No
2021-02-02 Dube Eric M Chief Executive Officer Sell 8,734 $29.91 $261,267 No
2021-02-02 Clague Laura Chief Financial Officer Sell 3,625 $30.75 $111,469 No
2021-02-02 ASELAGE STEVE Director Sell 25,000 $30.75 $768,750 Yes
2021-01-06 REED ELIZABETH E SVP, GC & Corporate Secretary Sell 1,376 $26.83 $36,918 No
2021-01-06 Dube Eric M Chief Executive Officer Sell 6,876 $26.83 $184,483 No
2020-12-15 ASELAGE STEVE Director Sell 5,549 $26.02 $144,385 No
2020-12-02 ASELAGE STEVE Director Sell 7,891 $23.43 $184,849 No
2020-11-25 Clague Laura Chief Financial Officer Sell 7,500 $23.29 $174,675 No

Insider Smart

SIMON PROPERTY GROUP (SPG) - Bottom fishing the crash could be intimidating, but it can be easier if you know insiders are on your side. Aeppel Glyn, Director of SPG played safe and bought shares in May at $50, but it is not late at all, the stock is now $90.

Insider Smart

Ovintiv Inc (OVV) - Insiders of OVV have been HEAVILY accumulating shares in March with a sub-$3 cost. And the stock is now $11. An awesome 400% gain can't be missed if you found it was heavily accumulated earlier.